Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism

Tsuyoshi Yoshida, Yasuo Kuwabara, Yuichi Ichiya, Masayuki Sasaki, Toshimitsu Fukumura, Atsushi Ichimiya, Masashi Takita, Koji Ogomori, Kouji Masuda

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We studied the cerebral muscarinic acetylcholinergic receptor (mACh-R) by means of 11C-N-methyl-4-piperidyl benzilate (11C-NMPB) and positron emission tomography (PET) in Alzheimer's disease (AD) cases, and the findings were compared with the cerebral blood flow (CBF) and the glucose metabolism (CMRGlc) to evaluate the relationship between the mACh-R and the CBF or the CMRGlc. The subjects consisted of 18 patients with AD and 18 age and sex matched normal volunteers. The patients were clinically diagnosed according to the criteria of the NINDS-ADRDA as having 'probable AD' and were thus classified into two groups (mild and moderate AD) according to the severity of dementia determined by DSM-III-R. The CBF was measured by (99m)TcHMPAO SPECT, and the CMRGlc was measured by 18FDG PET. The 11C-NMPB uptake was evaluated by the graphical method and the ratio method (ROIs/Cerebellum). A significant mAChR decrease and more severe CMRGlc decrease in the conical region was seen in mild and moderate AD. The decrease in the CBF was not as obvious as that in the mACh-R and the CMRGlc. Our study thus suggested that the mACh-R decreased in patients with AD, and that the 18FDG PET was the most sensitive method for detecting the degenerative regions in patients with AD.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalAnnals of Nuclear Medicine
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 1 1998

Fingerprint

Cerebrovascular Circulation
Muscarinic Receptors
Alzheimer Disease
Glucose
Positron-Emission Tomography
Fluorodeoxyglucose F18
National Institute of Neurological Disorders and Stroke
enpiperate
Single-Photon Emission-Computed Tomography
Diagnostic and Statistical Manual of Mental Disorders
Cerebellum
Dementia
Blood Glucose
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism. / Yoshida, Tsuyoshi; Kuwabara, Yasuo; Ichiya, Yuichi; Sasaki, Masayuki; Fukumura, Toshimitsu; Ichimiya, Atsushi; Takita, Masashi; Ogomori, Koji; Masuda, Kouji.

In: Annals of Nuclear Medicine, Vol. 12, No. 1, 01.01.1998, p. 35-42.

Research output: Contribution to journalArticle

Yoshida, Tsuyoshi ; Kuwabara, Yasuo ; Ichiya, Yuichi ; Sasaki, Masayuki ; Fukumura, Toshimitsu ; Ichimiya, Atsushi ; Takita, Masashi ; Ogomori, Koji ; Masuda, Kouji. / Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism. In: Annals of Nuclear Medicine. 1998 ; Vol. 12, No. 1. pp. 35-42.
@article{21b819e466f44b18a1670d3183fb6a48,
title = "Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism",
abstract = "We studied the cerebral muscarinic acetylcholinergic receptor (mACh-R) by means of 11C-N-methyl-4-piperidyl benzilate (11C-NMPB) and positron emission tomography (PET) in Alzheimer's disease (AD) cases, and the findings were compared with the cerebral blood flow (CBF) and the glucose metabolism (CMRGlc) to evaluate the relationship between the mACh-R and the CBF or the CMRGlc. The subjects consisted of 18 patients with AD and 18 age and sex matched normal volunteers. The patients were clinically diagnosed according to the criteria of the NINDS-ADRDA as having 'probable AD' and were thus classified into two groups (mild and moderate AD) according to the severity of dementia determined by DSM-III-R. The CBF was measured by (99m)TcHMPAO SPECT, and the CMRGlc was measured by 18FDG PET. The 11C-NMPB uptake was evaluated by the graphical method and the ratio method (ROIs/Cerebellum). A significant mAChR decrease and more severe CMRGlc decrease in the conical region was seen in mild and moderate AD. The decrease in the CBF was not as obvious as that in the mACh-R and the CMRGlc. Our study thus suggested that the mACh-R decreased in patients with AD, and that the 18FDG PET was the most sensitive method for detecting the degenerative regions in patients with AD.",
author = "Tsuyoshi Yoshida and Yasuo Kuwabara and Yuichi Ichiya and Masayuki Sasaki and Toshimitsu Fukumura and Atsushi Ichimiya and Masashi Takita and Koji Ogomori and Kouji Masuda",
year = "1998",
month = "1",
day = "1",
doi = "10.1007/BF03165414",
language = "English",
volume = "12",
pages = "35--42",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism

AU - Yoshida, Tsuyoshi

AU - Kuwabara, Yasuo

AU - Ichiya, Yuichi

AU - Sasaki, Masayuki

AU - Fukumura, Toshimitsu

AU - Ichimiya, Atsushi

AU - Takita, Masashi

AU - Ogomori, Koji

AU - Masuda, Kouji

PY - 1998/1/1

Y1 - 1998/1/1

N2 - We studied the cerebral muscarinic acetylcholinergic receptor (mACh-R) by means of 11C-N-methyl-4-piperidyl benzilate (11C-NMPB) and positron emission tomography (PET) in Alzheimer's disease (AD) cases, and the findings were compared with the cerebral blood flow (CBF) and the glucose metabolism (CMRGlc) to evaluate the relationship between the mACh-R and the CBF or the CMRGlc. The subjects consisted of 18 patients with AD and 18 age and sex matched normal volunteers. The patients were clinically diagnosed according to the criteria of the NINDS-ADRDA as having 'probable AD' and were thus classified into two groups (mild and moderate AD) according to the severity of dementia determined by DSM-III-R. The CBF was measured by (99m)TcHMPAO SPECT, and the CMRGlc was measured by 18FDG PET. The 11C-NMPB uptake was evaluated by the graphical method and the ratio method (ROIs/Cerebellum). A significant mAChR decrease and more severe CMRGlc decrease in the conical region was seen in mild and moderate AD. The decrease in the CBF was not as obvious as that in the mACh-R and the CMRGlc. Our study thus suggested that the mACh-R decreased in patients with AD, and that the 18FDG PET was the most sensitive method for detecting the degenerative regions in patients with AD.

AB - We studied the cerebral muscarinic acetylcholinergic receptor (mACh-R) by means of 11C-N-methyl-4-piperidyl benzilate (11C-NMPB) and positron emission tomography (PET) in Alzheimer's disease (AD) cases, and the findings were compared with the cerebral blood flow (CBF) and the glucose metabolism (CMRGlc) to evaluate the relationship between the mACh-R and the CBF or the CMRGlc. The subjects consisted of 18 patients with AD and 18 age and sex matched normal volunteers. The patients were clinically diagnosed according to the criteria of the NINDS-ADRDA as having 'probable AD' and were thus classified into two groups (mild and moderate AD) according to the severity of dementia determined by DSM-III-R. The CBF was measured by (99m)TcHMPAO SPECT, and the CMRGlc was measured by 18FDG PET. The 11C-NMPB uptake was evaluated by the graphical method and the ratio method (ROIs/Cerebellum). A significant mAChR decrease and more severe CMRGlc decrease in the conical region was seen in mild and moderate AD. The decrease in the CBF was not as obvious as that in the mACh-R and the CMRGlc. Our study thus suggested that the mACh-R decreased in patients with AD, and that the 18FDG PET was the most sensitive method for detecting the degenerative regions in patients with AD.

UR - http://www.scopus.com/inward/record.url?scp=0031953757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031953757&partnerID=8YFLogxK

U2 - 10.1007/BF03165414

DO - 10.1007/BF03165414

M3 - Article

C2 - 9559960

AN - SCOPUS:0031953757

VL - 12

SP - 35

EP - 42

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 1

ER -